Detalhe da pesquisa
1.
Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing.
Cell
; 179(5): 1207-1221.e22, 2019 Nov 14.
Artigo
Inglês
| MEDLINE | ID: mdl-31730858
2.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38507751
3.
Genome of a middle Holocene hunter-gatherer from Wallacea.
Nature
; 596(7873): 543-547, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34433944
4.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34914339
5.
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
JAMA
; 331(13): 1135-1144, 2024 04 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38563834
6.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31826360
7.
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
Future Oncol
; 19(8): 559-573, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37070653
8.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33794206
9.
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Br J Cancer
; 125(5): 679-686, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34158598
10.
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Oncologist
; 26(7): e1133-e1142, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33909934
11.
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.
Nature
; 518(7539): 422-6, 2015 Feb 19.
Artigo
Inglês
| MEDLINE | ID: mdl-25470049
12.
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.
J Oncol Pharm Pract
; 27(6): 1371-1381, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-32847480
13.
Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy.
Oncologist
; 25(3): 212-217, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32162800
14.
Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
Breast Cancer Res Treat
; 184(3): 755-762, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-33001336
15.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32274665
16.
Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing.
Genet Med
; 22(11): 1892-1897, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32624572
17.
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
Invest New Drugs
; 38(5): 1601-1604, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31907737
18.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30509771
19.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30867034
20.
Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?
Br J Cancer
; 121(1): 1-2, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31171836